Sharma P, et al. - In this phase 1/2 multicenter study, researchers report the nivolumab 1 mg/kg plus ipilimumab 3 mg/kg expansion cohort results of CheckMate 032 study wherein nivolumab 3 mg/kg monotherapy every 2 weeks (NIVO3), nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for four doses followed by nivolumab monotherapy 3 mg/kg every 2 weeks (NIVO3+IPI1), or nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks for four doses followed by nivolumab monotherapy 3 mg/kg every 2 weeks (NIVO1+IPI3) were used to treat patients with unresectable locally advanced or metastatic urothelial carcinoma. They also report extended follow-up for the NIVO3 and NIVO3+IPI1 cohorts. According to the findings of a longer follow-up, sustained antitumor activity was displayed by NIVO3, both alone and in combination with ipilimumab. A manageable safety profile, as well as the greatest antitumor activity among all regimens was shown by NIVO1+IPI3. The potential advantage of immunotherapy combinations in this disease was suggested.